Regional Analysis
Global Anti-Radiation Drugs Market- Regional Insights
- North America is expected to be the largest market for anti-radiation drugs market during the forecast period, and accounted for over 40% of the market share in 2022. North America market growth is attributed to high adoption of radiation therapy, increasing prevalence of cancer, and presence of leading market players.
- The Europe market is expected to be the second-largest market for anti-radiation drugs market, and accounted for over 30% of the market share in 2022. Europe market growth is attributed to rising cases of cancer, supportive government initiatives, and investments in R&D.
- The Asia Pacific market is expected to be the fastest-growing market for anti-radiation drugs market, with a CAGR of over 15% during the forecast period. Asia Pacific market growth is attributed to improving healthcare infrastructure, rising disposable incomes, and increasing awareness about radiation therapy.
| Geographies covered: |
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
|
U.S.: 
U.K. : 
India : 
